Comparison of two antiretroviral regimens in HIV Post-exposure Prophylaxis: TDF-FTC (Truvada) + Lopinavir/ritonavir (kaletra) versus TDF-FTC (Truvada) + raltegravir (Isentress). A prospective, randomized, open clinical trial.

Trial Profile

Comparison of two antiretroviral regimens in HIV Post-exposure Prophylaxis: TDF-FTC (Truvada) + Lopinavir/ritonavir (kaletra) versus TDF-FTC (Truvada) + raltegravir (Isentress). A prospective, randomized, open clinical trial.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Mar 2016

At a glance

  • Drugs Raltegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate; Lopinavir/ritonavir
  • Indications HIV infections
  • Focus Adverse reactions
  • Acronyms RAL-PEP
  • Most Recent Events

    • 18 Mar 2016 Results published in the Journal of Antimicrobial Chemotherapy
    • 25 May 2015 Status changed from recruiting to completed.
    • 11 Apr 2012 Additional lead trial centre, investigator (Garcia Felipe, MD) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top